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No objective parameters have been found so far that
can predict the biological behavior of early stages of
prostatic cancer, which are encountered frequently
nowadays due to surveillance and screening pro-
grams. We have applied comparative genomic hybrid-
ization to routinely processed, paraffin-embedded
radical prostatectomy specimens derived from pa-
tients who participated in the European Randomized
Study of Screening for Prostate Cancer. We defined a
panel consisting of 36 early cancer specimens: 13
small (total tumor volume (Tv) < 0.5 ml) carcinomas
and 23 intermediate (Tv between 0.5–1.0 ml) tumors.
These samples were compared with a set of 16 locally
advanced, large (Tv > 2.0 ml) tumor samples, not
derived from the European Randomized Study of
Screening for Prostate Cancer. Chromosome arms
that frequently (ie, >15%) showed loss in the small
tumors included 13q (31%), 6q (23%), and Y (15%),
whereas frequent (ie, >15%) gain was seen of 20q
(15%). In the intermediate cancers, loss was detected
of 8p (35%), 16q (30%), 5q (26%), Y (22%), 6q, and
18q (both 17%). No consistent gains were found in
this group. In the large tumors, loss was seen of 13q
(69%), 8p (50%), 5q, 6q (both 31%), and Y (15%).
Gains were observed of 8q (37%), 3q (25%), 7p, 7q,
9q, and Xq (all 19%). Comparison of these early,
localized tumors with large adenocarcinomas showed
a significant increase in the number of aberrant chro-
mosomes per case (Rs 5 0.36, P 5 0.009). The same
was true for the number of lost or gained chromo-
somes per case (Rs 5 0.27, P 5 0.05; Rs 5 0.48,
respectively; P < 0.001). Interestingly, chromosomal
alterations that were found in previous studies to be
potential biomarkers for tumor aggressiveness, ie,
gain of 7pq and/or 8q, were already distinguished in
the small and intermediate cancers. In conclusion,
our data show that chromosomal losses, more specif-
ically of 6q and 13q, are early events in prostatic
tumorigenesis, whereas chromosomal gains, espe-
cially of 8q, appear to be late events in prostatic
tumor development. Finally, early localized tumors,
as detected by screening programs, harbor cancers
with aggressive genetic characteristics. (Am J Pathol
2001, 158:399–406)
The incidence of prostate cancer has dramatically in-
creased during the last two decades. It is now the most
commonly diagnosed noncutaneous malignancy in men
in Western countries with a high socio-economic stan-
dard, and its mortality is surpassed only by that of lung
cancer.1 The exponential increase in incidence, which
peaked in the early 1990s,2 has been largely attributed to
the increased use of prostate-specific antigen (PSA) in
prostate carcinoma detection and population-based
screening programs, rather than considered a true in-
crease in incidence.3,4 These surveillance and early de-
tection programs have led to an increasing number of
patients being diagnosed with early, clinically localized
prostate carcinoma.2,4,5 On the one hand, patients with
these tumors likely benefit from curative treatment and
mostly have a good prognosis after therapy.6,7 On the
Supported by the Dutch Cancer Society Grant EUR 97–1404 and the
Sascha Swarttouw-Hijmans Foundation.
Accepted for publication October 13, 2000.
Address reprint requests to Dr. Janneke C. Alers, Department of Pathol-
ogy, Josephine Nefkens Institute, Erasmus University Rotterdam, P.O. Box
1738, 3000 DR Rotterdam, The Netherlands. E-mail: alers@path.fgg.eur.nl.
American Journal of Pathology, Vol. 158, No. 2, February 2001
Copyright © American Society for Investigative Pathology
399
Table 1. Clinicopathological Data and Results of CGH Analysis
Case
Age
(years)
Pre-
operative
PSA
(ng/ml)
Pre-
operative
clinical
stage T*
pT
stage
Tumor
volume
(ml)
Gleason
score CGH loss CGH gain
1 57 2.2 T2a pT2a 0.04 6 8p11.2-p22
2 57 2.1 T2a pT2b 0.12 6
3 62 2.4 T2b pT2b 0.18 5
4 56 5.6 T2a pT2a 0.20 7
5 69 6.5 T3a pT2b 0.21 6
6 61 1.2 T2a pT2b 0.23 6 4q27, 6p21.3-p23, 6q14-
q21, 7p13-p15, 7q11.2,
13q12-q22, Y
7 58 1.2 T2a pT2b 0.32 5 13q14-q31
8 56 1.3 T2x pT2a 0.35 6 5q11.2, 5q15-q22, 6q12-
q21, Y
3q13.2-q22, 4p15.3-pter,
8q23-qter, 20q13.1-
q13.2
9 66 13.5 T2a pT2b 0.36 6 6q21-q22, 13q14-q21
10 65 4.1 T1c pT2a 0.38 6
11 62 3.6 T2x pT2b 0.38 6 9q31-qter, 17q23-qter,
20q12
12 61 0.4 T2a pT2b 0.43 6
13 57 0.9 T2a pT2a 0.46 6 3q13.1-q21, 13q21-q22 16p11.2-pter
14 62 3.0 T2x pT2b 0.50 7 3p24-pter, 5q14-q23, 5q31,
6q15-q21, 8p11.2-p22,
18q21-q22
15 66 9.1 T2a pT2b 0.51 6 5p13-pter, 5q12-q13
16 59 7.2 T1c pT2a 0.52 6 6q22-q25, 16q13-q23
17 62 8.0 n.a. pT2b 0.53 7 9p21-p23, 11p13-p14
18 64 3.9 T3x pT2b 0.55 7 2q21-q31, 8p11.2-p21,
11q14-q22, 12p11.2, Y
5p12-pter
19 58 4.7 T1c pT2a 0.55 6 6q15-q22, 16q12.1-q23,
18q21, Xq21-q26, Y
8q11.2-qter
20 64 1.6 T1c† pT2b 0.58 6 4p12-p15.3, 4q12-q21,
16q22-qter
21 70 6.4 T2a pT2b 0.59 7
22‡ 64 3.9 n.a. pT2b 0.61 7 16q12.2-qter
23 62 1.5 T2b pT2b 0.61 5 5q12-q21, 9p13-p22,
12p11.2-p12, 13q21
24 66 2.9 T2a pT2b 0.63 7 5q14-q21, 6q16-q21, 8p12-
p22, 18q21, Y
#7
25 65 13.0 T1c pT2b 0.63 7 8p11.2-p23, 16p12-p13.1,
18q11.2-qter, Y
8q21.1-q22, 12p12
26 60 3.7 T2a pT2b 0.64 7 5p15.1, 5q14-q23, 11q14-
q24, 14q24-q31, 16q21-
qter
3q13.3-q21
27 70 2.8 T1c§ pT2b 0.69 7 3p13-p21, 8p12-p21, 16q22-
q23
3q24, 4q24-q26, 4q32,
7p13-p14, 9q21
28 69 4.4 T2a pT2b 0.70 6 12p13, 17p11.2-pter
29‡ 60 4.8 T1c pT2b 0.77 5 10p11.2-p13
30 66 10.6 T3a pT2a 0.78 7 2q13-q22, 8p11.2-p21 7q11.2-q21
31‡ 71 4.7 T2a pT2b 0.83 7 5q23-q31, 8p21-pter, 16q23 8q11.2-qter
32 63 3.6 T2a pT2b 0.84 7 2q14.2-q21, 13q14-q21, Y
33 57 4.1 T2a pT2b 0.84 6 Xp11.2-p22.1
34 73 8.3 T2a pT2b 0.85 7
35‡ 70 5.8 T1c pT2b 0.85 5 8p11.2-p22
36 57 4.6 T1c pT2b 0.90 5
37 59 17.2 T3x pT2b 2.1 7 8p11.2-pter, 12p11.2-pter
38 51 16.1 T2a pT2a 2.2 7 13q21
39 66 5.0 T2b pT3a 2.3 7 13q14-q21 3p12-pter, 3q13.3-qter
40 47 11.2 T3x pT3a 2.3 7 5q12-q33, 8p21-pter, 9p13-
pter, 13q21-qter, Y
3q21
41 63 4.5 T3x pT3a 2.4 5 2q21-q22, 4q22-q27, 6q13-
q22, 13q13-q31
5q34-qter, 9q32-qter
42 66 5.8 T2a pT2b 2.4 5 8p11.2-p22, 16q22-q23
43 53 16.5 T3x pT3a 4.2 7 6q12-q25, 13q13-q21 # X
44 60 32.9 T3x pT3x 6.0 10 6q12-q16, 8p11.2-pter,
13q12-qter, 16q12.1-qter,
18q11.2-qter, 22q11.2
1q21-qter, 1p31-pter,
1p13, 3p24-pter, 3p13-
p21, 7q11.2-q32, 8q21-
qter, 9p23-p24, 9q13-
qter, 11q12-qter
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other hand, with increased detection comes the risk of
finding small, organ-confined, well differentiated tumors,
which may pose relatively little threat to the patient.6–10
The latter category of cancers might best be left un-
treated, especially in older patients,7,11 if they could be
clearly identified on a pretreatment basis. However, the
available diagnostic tools fail to provide consistent pre-
dictive information for firm clinical decisionmaking in in-
dividual cases.7 The analysis of molecular (cyto)genetic
changes associated with the initiation and progression of
prostate cancer may enable us to establish accurate
methods of prognostication when the disease is encoun-
tered in its earliest stages of development.
Conventional cytogenetic studies of prostatic adeno-
carcinoma have consistently revealed loss of the Y chro-
mosome, trisomy of chromosome 7, del(7)(q22),
del(8)(p21), and del(10)(q24).12 Loss of heterozygosity
(LOH) analyses have shown frequent loss on chromo-
some arms 3p, 6q, 7q, 8p, 9p, 10pq, 13q, 16q, 17q, and
18q.13–24 Furthermore, comparative genomic hybridiza-
tion (CGH) applied to primary tumors revealed losses of
5q, 6q, 8p, and 13q, as well as gain of 8q in over 30% of
cases.25,26 CGH studies of advanced stages of prostate
cancer detected frequent ($50%) loss of 5q, 6q, 8p, 10q,
13q, 16q, and 17p, as well as gain of 1q, 3q, 7pq, 8q,
11p, 17q, and Xpq sequences.25–28 Fluorescent in situ
hybridization studies revealed numerical alterations of
chromosomes 7, 8, 10, 16, 17, 18, X, and Y,12,29 as well
as deletions and amplifications of specific chromosomal
regions, eg, loss of 8p2230 and gain of MYC on 8q24.31
Furthermore, we25,32 and others33,34 have identified al-
terations of chromosomes 7 and/or 8 as potential tumor
progression markers. Altogether, these molecular (cyto)-
genetic studies have identified multiple, non-random ge-
netic alterations in prostate cancer. However, at present,
knowledge concerning the initial stages of prostate can-
cer is very limited.
In the present study we have applied CGH to a unique
panel of archival tumor material obtained from patients
who participated in the European Randomized Study of
Screening for Prostate Cancer (ERSPC).35 To the best of
our knowledge, this is the first study to present molecular
cytogenetic data concerning tumors derived from a pop-
ulation-based screening program. Our goals were (i) to
obtain an overview of chromosomal alterations occurring
in these early, localized prostate cancers; (ii) to compare
the molecular cytogenetic characteristics of these tumors
with those of larger, clinically apparent prostate cancers;
and (iii) to see whether early cancers, as detected by
screening programs, harbor tumors with aggressive ge-
netic features.
Materials and Methods
Patient Material
The original screening algorithm of the screening arm of
the Rotterdam section of the ERSPC called for a biopsy in
all men who had at least one of the following results: a
suspicious digital rectal examination (DRE), a suspicious
transrectal ultrasound (TRUS), or a PSA level $4.0 ng/ml.
In March 1997, a major protocol change was imple-
mented within the ERSPC, when the study group decided
to perform a biopsy on all men with PSA levels $3.0
ng/ml, irrespective of findings on DRE or TRUS. DRE and
Table 1. Continued
Case
Age
(years)
Pre-
operative
PSA
(ng/ml)
Pre-
operative
clinical
stage T*
pT
stage
Tumor
volume
(ml)
Gleason
score CGH loss CGH gain
45 63 18.7 T3x pT4 6.9 7 5q15-q23, 6q13-q22,
8p11.2-pter, 11q14-q23,
12q15-q21, 13q13-q21
3q12-qter, 7p11.2-pter,
7q11.2-q31, 8q24.1-qter
46 55 13.2 T2a pT4 7.0 7 5q11.2, 13q21, Y 2q35-qter, 8q24.1-qter,
9q32-qter, Xq27-qter
47 51 2.8 T2a pT4 7.2 6 1p13-p31, 3q24-q25, 4q23-
q28, 5q14-q21, 13q14-
q31
6p21.1-p21.3, 7p21-pter,
14q24.3-qter, 20q11.2-
qter
48 57 12.4 T2a pT4 9.8 7 4q12-q13, # X
49 65 181.4 T2a pT4 12.5 9
50 58 108 T2b pT4 14.8 5 8p11.2-p22, 13q13-q21, Y 8q22-qter
51 64 5.9 T4x pT4 15.7 9 6q11.2-q24, 8p11.2-pter,
13q14-qter
2q32-qter, 6p11.2-pter,
8q23-qter, 17q23-qter
52 67 32 T3x pT4 21.6 9 5q14-q21, 8p11.2-pter,
12p11.2-pter
1q23-q31, 3q26.1-q27,
7p11.2-pter, 7q21,
7q32-qter, 8q12-qter
* Staging of localized prostatic adenocarcinoma (all N0M0) according to the clinical and pathological (pT) TNM classification 1997
36 T1c, clinically
inapparent tumor, not palpable nor visible by imaging, identified by needle biopsy (e.g. because of elevated PSA); T2, tumor confined to prostate,
involving 1 lobe (T2a), or both lobes (T2b); T3 tumor extends through prostatic capsule (T3a) or tumor invades seminal vesicle(s) (T3b); T4, tumor
is fixed or invades adjacent structures other than seminal vesicles, including microscopic invasion of bladder wall; Tx primary tumor cannot be
assessed.
† PSA at time of biopsy 3.1 ng/ml.
‡ These patients showed biochemical progression in follow-up.
§ PSA at time of biopsy 5.5 ng/ml.
n.a., not available.
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TRUS were omitted as a screening tool if an individual’s
PSA level was ,3.0 ng/ml.35 Approximately half of the
patients with a positive biopsy were treated by radical
prostatectomy. We collected formalin-fixed, paraffin-em-
bedded materials, obtained between 1994 and 1998,
derived from radical prostatectomies of 36 patients par-
ticipating in the first round of the ERSPC. These samples
were compared with a set of 16 archival, clinically appar-
ent tumors, obtained between 1990 and 1992 and not
derived from the ERSPC study.
After fixation, each specimen was step-sectioned at
4-mm intervals and totally embedded in paraffin blocks
as described previously.36 From each paraffin block,
standard hematoxylin-eosin-stained slides were pre-
pared for routine histopathological examination, includ-
ing determination of pathological TNM stage37 and Glea-
son score38 (see Table 1). Tumor volumes were
measured as reported before.36 Briefly, after histological
examination, all areas containing cancer were outlined on
the slides. Digital morphometric analysis (Kontron Imag-
ing System, model KS 400; Kontron Elektronik GmbH,
Eching, Germany; ERSPC cancers) and/or a microscopic
grid method (non-ERSPC cancers) was performed to
measure each tumor area . The two methods correlated
excellently (Rs 5 1.00; P , 0.001). We determined the
total tumor volume (Tv) by adding all measured tumor
areas (in mm2) and multiplying them by 4 (ie, the thick-
ness, in millimeters, of the original slices). On the basis of
their total tumor volume, our set of 52 tumors (all periph-
eral zone adenocarcinomas) was arbitrarily divided into
three categories: 13 small (Tv , 0.5 ml) carcinomas, 23
intermediate (Tv between 0.5–1.0 ml) tumors, and 16
large (Tv . 2.0 ml) tumor samples (Table 1). The subdi-
vision of the early cancers in small and intermediate
tumors was based partially on data from literature, in
which it was reported that localized (pT2) tumors with a Tv
,0.5 ml and lacking a Gleason growth pattern of 4 or 5
may be considered insignificant and/or minimal9,36 or
clinically unimportant.10
CGH of Archival Material
Isolation of DNA from the formalin-fixed, paraffin-embed-
ded tumor material was performed as described by Alers
et al.32 Briefly, the tissue blocks were counterstained in
49,6-diamidino-2-phenylindole (DAPI) and placed under
a fluorescence microscope, enabling a precise selection
of the tumor area. Microdissection of the tumor areas was
performed using a hollow bore coupled to the micro-
scope. In cases of very small tumor areas, manual micro-
dissection of the selected areas was performed by scrap-
ing successive hematoxylin-stained 10-mm tissue
sections using a hollow needle under a stereo micro-
scope. Lower boundaries were checked for the presence
of tumor on 4-mm hematoxylin-eosin-stained tissue sec-
tions. Isolation of DNA from the formalin-fixed, paraffin-
embedded material was performed using the Puregene
DNA isolation kit (Gentra Systems, Minneapolis, MN).
Tumor DNA with a fragment size ,1 kb was chemically
labeled with biotin-universal linkage system (Kreatech
Diagnostics, Amsterdam, The Netherlands).39 Tumor
DNA with larger DNA fragment sizes was labeled with
biotin by nick translation (Nick Translation System, Gibco
BRL, Gaithersburg, MD). Likewise, male reference DNA
(Promega, Madison, WI) was labeled by nick translation
with digoxigenin (Boehringer Mannheim, Indianapolis,
IN). The reaction time and the amount of DNase were
adjusted to obtain a matching probe size for reference
and tumor DNAs. The labeled DNAs were hybridized
onto normal male metaphase chromosomes (Vysis Inc.,
Downers Grove, IL), as described previously.25,32,40
CGH analysis was accomplished with Quips XL software
from Vysis (version 3.1.1). Loss of DNA sequences was
defined as chromosomal regions where the mean green:
red ratio was below 0.85, whereas gain was defined as
chromosomal regions where the ratio was above 1.15.
These threshold values were based on series of normal
controls. Some chromosomal alterations, such as simul-
taneous gains of chromosome 1pter, 9q34, 11q13, #19,
and 22q, were disregarded and excluded from analysis,
since these areas are known to present variation in nor-
mal controls.41 In contrast to some other studies, we have
included genomic imbalances of the Y chromosome as
we have confirmed CGH data by in situ hybridization
results with a chromosome Y-specific DNA probe.
Statistical Analysis
Percentages between groups were compared using
Fisher’s exact test or the x2 test for trend if indicated.
Comparison between percentages of chromosomal alter-
ations between groups were only performed if the alter-
ation occurred in .10% of total cases. Comparison of the
average number of aberrations and clinical stage was
performed using the Mann-Whitney U test. Correlation
coefficients (Rs) given are Spearman’s. Multivariate anal-
ysis using multiple regression was performed to investi-
gate which of the clinicopathological parameters, ie, tu-
mor volume, pathological tumor stage, and pathological
grade, played a dominant role regarding the genetic
changes found. In this analysis, Tv and the dependent
variable, ie, the number of aberrant, lost, or gained chro-
mosomes per case, had to be transformed logarithmi-
cally to reduce skewness of the distributions. P 5 0.05
(two-sided) was considered the limit of significance.
Results
Overview of Genetic Changes
Clinicopathological data and results of CGH analysis of
patients with different tumor volumes, ie, 13 small tumors
(Tv , 0.5 ml), 23 intermediate tumors (Tv 0.5–1.0 ml; all 36
cases derived from ERSPC), and 16 large (Tv . 2.0 ml
tumors; not derived from ERSPC), are summarized in
Table 1 and Figure 1.
In small carcinomas, chromosomal losses were seen
repetitively of 13q (31%), 6q (23%), and Y (15%),
whereas gain of 20q was observed in 15% of cases
(Figure 1A). In the intermediate tumors losses were most
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often detected of 8p (35%), 16q (30%), 5q (26%), Y
(22%), 6q, and 18q sequences (both 17%), whereas no
recurrent gains were seen (Figure 1B). However, gain of
7pq and/or gain of 8q sequences, potential biomarkers
for tumor aggressiveness identified in previous stud-
ies,25,32–34 were already encountered in 19% of the early
(ie, small and intermediate combined) cancers. In the
large cancers, frequent loss was observed of 13q (69%),
8p (50%), 5q, 6q (both 31%), and Y (15%; Figure 1C).
Gains most often involved 8q (37%), 3q (25%), 7p, 7q,
9q, and Xq (all 19%; Figure 1C).
Genetic Changes and Tumor Volume
The results of CGH analysis of the three different tumor
volume groups are presented in Figure 2, whereas sta-
tistical correlations between different clinicopathological
parameters and chromosomal alterations, as detected by
CGH, are depicted in Table 2.
The number of cases showing a chromosomal aberra-
tion significantly increased, from 54% in small cancers to
87% in intermediate tumors to 94% in large cancers
(Ptrend 5 0.009). Also, the number of cases showing loss
or gain was higher in larger tumors (Ptrend 5 0.01 and
Ptrend 5 0.005, respectively; Table 2). Furthermore, the
average number of aberrant chromosomes per case in-
creased along with the exact tumor volume (Table 2,
Figure 2; Rs 5 0.36, P 5 0.009). The same was true for
the number of chromosomes showing loss or gain per
case (Table 2, Figure 2; Rs 5 0.27, P 5 0.05; Rs 5 0.48,
respectively; P , 0.001).
A gradual increase was seen of cases with loss of 8p,
going from 8% in small cancers to 35% in intermediate
tumors to 50% in large carcinomas (Table 2; Ptrend 5
0.02). Likewise, a significant rise in cases with gain of 8q
sequences was observed with increasing tumor volume
(Table 2; Ptrend 5 0.04). Potential biomarkers for tumor
aggressiveness, ie, gain of 7pq and/or 8q, were less
frequently discriminated in the small (8%) and intermedi-
ate cancers (26%) than in the large tumor samples (44%;
Table 2; Ptrend 5 0.03).
Genetic Changes and Clinicopathological
Parameters
As shown in Table 2, the average number of chromo-
somes with aberrations, especially gains, per case in-
creased with tumor stage and grade. More specifically,
an increase in the number of cases with gain of 8q
sequences was found in high stage, high grade tumors.
For corresponding P values, see Table 2. Further, no
differences were found for the molecular cytogenetic pa-
rameters described here between preoperative clinical
stage T1c (nonpalpable, invisible) versus T2/T3 (palpa-
ble) tumors (all P values .0.5; Table 1). In addition, it
appeared that the clinicopathological parameters of tu-
mor volume, pathological tumor stage, and pathological
grade (Gleason score) were closely related (tumor vol-
ume versus stage Rs 5 0.75, P , 0.001; tumor volume
versus grade Rs 5 0.37, P 5 0.006; stage versus grade
Rs 5 0.35, P 5 0.01). Multiple regression analysis of
these features showed that for most of the genetic pa-
rameters described here, no significant additional pre-
dictive value on top of tumor volume was observed for
Figure 1. Chromosomal ideograms showing the summary of DNA copy
number changes, detected by CGH, in tumors of 52 patients with different
tumor volumes. Losses are displayed on the left of the ideogram, gains are
shown on the right. A: Small cancers (Tv , 0.5 ml; n 5 13), showing loss of
6q, 13q, and Y, as well as gain of 20q. B: Intermediate cancers (Tv between
0.5–1.0 ml; n 5 23), displaying loss of 5q, 6q, 8p, 16q, 18q, and Y. C: Large
cancers (Tv . 2.0 ml; n 5 16), revealing recurrent loss of 5q, 6q, 8p, 13q, and
Y and frequent gain of 3q, 7pq, 8q, 9q, and Xq sequences.
Figure 2. Comparison of the chromosomal aberrations between small, in-
termediate, and large prostate cancers, showing the average number (6
SEM) of altered chromosomes per patient. The average number of aberrant
chromosomes per patient significantly increased with increasing exact tumor
volume (Rs 5 0.36, P 5 0.009). The same was true for the number of
chromosomes showing loss or, especially, gain per case (Rs 5 0.27, P 5 0.05;
Rs 5 0.48, respectively; P , 0.001).
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Gleason score and stage. Due to the strong correlation
between tumor volume and tumor stage, however, the
effects of these parameters were difficult to separate.
Only for the number of chromosomal gains tumor stage
was a better predictor (P 5 0.04) than tumor volume (P 5
0.55).
Statistically significant correlations were found be-
tween preoperative PSA and tumor volume (Rs 5 0.61,
P , 0.001), preoperative PSA and tumor stage (Rs 5
0.51, P , 0.001), and preoperative PSA and grade (Rs 5
0.45, P 5 0.001), as has been described by others.42
Importantly, no direct correlations were observed be-
tween preoperative PSA levels and the molecular cyto-
genetic parameters mentioned here.
Discussion
This study reports for the first time a genome-wide survey
of the DNA copy number changes occurring in early
localized prostatic tumors derived from patients partici-
pating in a population-based screening study. Further-
more, the observed molecular cytogenetic changes were
correlated with tumor volume and different clinicopatho-
logical parameters. Our data show not only that larger
cancers have more frequent chromosomal alterations,
but also that more chromosomes are affected. This may
potentially be a result of an increased genetic instability
in larger tumors.43 Chromosomal losses, especially loss
of 6q and 13q, appeared to be relatively early changes in
prostatic tumor development, since they were already
frequently encountered in the small tumors. This sug-
gests that one or more tumor suppressor genes located
on these chromosomes may be important for prostatic
tumorigenesis. Loss of 6q sequences has been reported
to be both an early12 and a late event in prostatic tumor-
igenesis.14,26 In one study, it occurred in about one-third
of primary tumors and 73% of distant metastases.25 Loss
of 13q is a recurrent finding in LOH13,14,21 and CGH25–28
studies of prostate cancer, with frequencies ranging from
22%13 to as high as 91% in advanced cases.21 Allelic
loss of 6q and 13q was found in 18% and 8%, respec-
tively, of prostatic intraepithelial neoplasia (PIN) lesions, a
putative precursor lesion of prostate cancer, illustrating
their early appearance in prostatic tumor development.14
A gradual increase in the frequency of loss of 8p se-
quences was found with increasing tumor volume. In
contrast, Vocke et al18 did not find a correlation between
8p loss and tumor stage or grade. Loss of 8p is one of the
most common genetic alterations in prostate cancer, with
frequencies of 8p LOH as high as 86% in a large panel of
primary prostate cancers.18 LOH at 8p was also de-
scribed in PIN lesions,44,45 thereby being a possible
initial event in prostatic tumorigenesis. In the group of
early cancers, we found loss of 8p in nine cases (25%),
again revealing 8p loss as an early event. This percent-
age of 8p loss is somewhat lower than reported in LOH
studies, which may be due to the fact that the resolution
of CGH for detecting loss is approximately 10 Mb.46
Another recurrent finding, especially in the group of in-
termediate cancers, was the loss of 16q sequences. This
alteration was less prominent in the large cancers (12%),
which we attribute to sample size effects. Loss of 16q is
also one of the most consistent genetic alterations in
prostate cancer,13,14,22,25–28 with CGH analyses report-
ing frequencies ranging from 19% in primary tumors to
56% and 55% in recurrent cancers and metastases, re-
spectively.26,27 Loss of 5q appeared a relatively frequent
finding in our panel of both intermediate and large can-
cers. This alteration has been predominantly reported in
advanced tumors.14,25–27 Y chromosome loss was also
an early finding, occurring already in the small and inter-
mediate cancers. We have seen loss of Y throughout the
spectrum of prostatic tumorigenesis, ranging from PIN
lesions47 to distant metastases.32
Chromosomal gains were found to be relatively late
events in prostatic tumor development, as can be seen
by a sharp increase in the average number of chromo-
somes with gains going from intermediate tumors to large
cancers (Figure 2). It suggests involvement of oncogenes
in later stages of prostatic tumorigenesis, as opposed to
the more gradual increase of loss of tumor suppressor
gene sites (Figure 2). Gains appeared to be adverse
prognostic indicators after radical prostatectomy.25 In
this study, a gradual increase was seen of the number of
cases with 8q gain with increasing tumor volume. In
several cases (Table 1), gain of (part of) 8q was accom-
panied by 8p loss. This may be suggestive for i(8q)
formation.32,48,49 In addition, gain of 8q has been re-
Table 2. Statistical Correlations between Clinicopathological Parameters and Genetic Changes as Detected by CGH
Tumor volume pT stage Pathological grade*
Number of cases with aberrations Ptrend 5 0.009 Ptrend 5 0.3, n.s. Ptrend 5 0.6, n.s.
Number of cases with loss Ptrend 5 0.01 Ptrend 5 0.6, n.s. Ptrend 5 0.6, n.s.
Number of cases with gain Ptrend 5 0.005 Ptrend , 0.001 Ptrend 5 0.02
Average number of aberrant chromosomes
per case
Rs 5 0.36, P 5 0.009 Rs 5 0.41, P 5 0.002 Rs 5 0.28, P 5 0.04
Average number of chromosomes with loss
per case
Rs 5 0.27, P 5 0.05 Rs 5 0.27, P 5 0.05 Rs 5 0.23, P 5 0.1, n.s.
Average number of chromosomes with gain
per case
Rs 5 0.48, P , 0.001 Rs 5 0.59, P , 0.001 Rs 5 0.36, P 5 0.008
Number of cases with 8p loss Ptrend 5 0.02 Ptrend 5 0.2, n.s. Ptrend 5 0.03
Number of cases with 8q gain Ptrend 5 0.04 Ptrend 5 0.001 Ptrend 5 0.03
Number of cases with gain of 7pq and/or 8q Ptrend 5 0.03 Ptrend 5 0.002 Ptrend 5 0.02
n.s., not statistically significant.
*Gleason score.
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ported in advanced stages of prostate cancer,25–28 and
appeared to be associated with short progression-free
survival.25,34,48 Interestingly, a gradual increase was
found for the number of cases with gain of 7pq and/or 8q
along with increasing tumor volume. Gains of chromo-
some 7 and/or 8 are regarded as potential biomarkers for
tumor aggressiveness.25,32–34 These alterations were
predominantly found in distant metastases and in primary
tumors that showed progression after radical prostatec-
tomy.25,32 Noteworthy, a subset of the tumors derived
from the ERSPC showed gain on chromosome 7pq
and/or 8q. Furthermore, other chromosomal alterations
that are reported in advanced stages of disease only,
such as chromosomal gains in general and loss of 5q and
16q sequences, were also seen in the early cancers.
These tumors may, therefore, be regarded as potentially
aggressive, which may have therapeutic implications.
Although the period of follow-up of these ERSPC pa-
tients is short at present (mean, 37.5 months; range,
6–62 months), preliminary data show that of the 36 pa-
tients described in this study, four patients with tumor
volumes between 0.5 and 1.0 ml have shown biochemi-
cal progression of the disease. All these cases displayed
chromosomal alterations, including one with 8q gain
combined with 8p loss (Table 1). This is in line with the
observation that the majority of nonpalpable, invisible
(T1c) tumors derived from screening programs, as
judged by their pathological characteristics, are clinically
significant tumors.2,9,10,36 Further follow-up studies of pa-
tients participating in population-based screening pro-
grams, such as ERSPC, will answer the question whether
the detection and treatment of early, localized tumors is
justified. Noteworthily, no direct correlations were ob-
served between preoperative PSA levels and the genetic
parameters mentioned here. Therefore, in our opinion, an
important role might be reserved for genetic biomarkers
that can predict the biological behavior of the tumor in the
earliest stages of clinical decisionmaking. Importantly,
this genetic test can be performed on archival prostatic
biopsies (Alers JC, unpublished results). Currently, we
are conducting a CGH study to examine whether the
pattern of genetic changes in pre-operative needle biop-
sies accurately represents the tumor in the correspond-
ing radical prostatectomy specimens. Finally, we are fur-
ther defining the 7pq-8q biomarker in a large cohort of
patients.
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